Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unnecessary stenting

This article was originally published in The Gray Sheet

Executive Summary

Duke University analysis places annual U.S. costs at up to $162 mil. Pooling results from seven different angioplasty trials including a total of 5,143 patients, researchers concluded that one of every 12 patients "may not need stents because their vessels are very unlikely to renarrow after balloon angioplasty." Candidates are likely to include males, patients with short atherosclerotic lesions, and lesions not at the top of the left anterior descending artery
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel